APOBEC3A-induced PD-L1 upregulation requires its deaminase activity and suggests APOBEC3A as an immune evasion mechanism and a potential target for improving cancer therapeutic efficacy of PD-1/PD-L1 targeting therapy. Here, APOBEC3A is linked to cancer.